Clinical trial · Interventional
A Study of Pre-operative Metformin in Prostate Cancer
A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling
NCT00881725CI-TRIAL-00007213ANIMATEterminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow Accrual
Summary
Brief summary (as posted)
This study will investigate the effect of neoadjuvant metformin therapy in the inhibition of growth and proliferation of prostate cancer cells prior to radical prostatectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metformin
- description
- 500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
- interventionNames
- Drug: Metformin
Primary outcomes (1)
- measure
- Difference in Ki67 staining
- timeFrame
- Pre-Surgery
Secondary outcomes (4)
- measure
- Other immunohistochemical assays: IR, IGF-1R, p70S6K, AMPK, MVD, Cleaved caspase 3, PTEN, c-Myc
- timeFrame
- Pre-Surgery
- measure
- Differences in measures of insulin resistance: waist/hip ratio, fasting blood glucose, post-prandial blood glucose, weight
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. 1\. Patients with histologically confirmed prostate cancer involving at least 20% of at least one unfragmented biopsy core; 2. Over the age of 18 and under the age of 75; 3. Ability to read and understand the consent form, either alone or with the aid of a translator 4. ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%); 5. Patients must have their TRUS biopsy performed at UHN (or at an outside institution if tissue accession can be arranged) in the last 3 months; 6. Patients must have normal organ and marrow function as defined by the following criteria: 1. Absolute neutrophil count greater than or equal to 1,500/uL 2. Platelets greater than or equal to 100,000/uL 3. Total bilirubin less than or equal to 1.5 X institutional ULN 4. AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional ULN 5. Creatinine less than or equal to 1.4 X institutional ULN Exclusion Criteria: 1. Patients who on initial assessment are found to be on treatment with any drug used for the treatment of any form of diabetes, or patients that begin treatment for any form of diabetes during the course of the study; 2. Patients may not be receiving any other investigational, herbal or anticancer agents while on study; 3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure (NYHA Class 3 or greater), cirrhosis with a Child-Pugh level of B or greater or evidence of cardiac dysfunction, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease, clinically significant gastrointestinal conditions (e.g. Crohns disease, ulcerative colitis), COPD or psychiatric illness/social situations that would limit compliance with study requirements; 4. Active malignancy at any other site excluding squamous cell or basal cell carcinomas of the skin 5. Radiotherapy within the past 4 weeks; 6. Patients with a current history of alcohol intake (\>2 standard drinks/day) or binge drinking (5 or more drinks (male), or 4 or more drinks (female)) in one session of 1-3 hours; 7. Past history of lactic acidosis or risk factors for lactic acidosis such as congestive heart failure (NYHA Class 3 or greater), hypoxia (resting PO2 \< 91%) or renal insufficiency (eGFR \< 60 mls/min) 8. Patients taking systemic glucocorticoids or estrogenic compounds. 9. Patients with known hypersensitivity or allergy to metformin or any of its excipients. 10. Patients with a history of impaired liver or kidney function.
References
Publications (5)
- BACKGROUNDJoshua AM, Evans A, Van der Kwast T, Zielenska M, Meeker AK, Chinnaiyan A, Squire JA. Prostatic preneoplasia and beyond. Biochim Biophys Acta. 2008 Apr;1785(2):156-81. doi: 10.1016/j.bbcan.2007.12.001. Epub 2007 Dec 8. PMID 18166163
- BACKGROUNDYoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007 Sep 3;97(5):678-85. doi: 10.1038/sj.bjc.6603924. Epub 2007 Aug 14. PMID 17700571
- BACKGROUNDSchmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer. 2007 Mar 15;120(6):1284-92. doi: 10.1002/ijc.22359. PMID 17163422
- BACKGROUNDHundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec;49(12):2063-9. doi: 10.2337/diabetes.49.12.2063. PMID 11118008
- BACKGROUNDMatsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol. 1994 Mar;14(3):2066-76. doi: 10.1128/mcb.14.3.2066-2076.1994. PMID 8114738